乙烷亚磺酸钠 | 20035-08-9

• 物质功能分类: 化学试剂 - 有机试剂 - 磺酸盐/亚磺酸盐
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 亚磺酸及其衍生物
• 中文名称: 乙烷亚磺酸钠
• 中文别名: 乙基亚磺酸钠
• 英文名称: sodium ethanesulfinate
• 英文别名: sodium ethylsulfinate；ethanesulfinic acid sodium salt；Natrium(ethansulfinat)；sodium;ethanesulfinate
• CAS: 20035-08-9
• 化学式: C₂H₅O₂S*Na
• 分子量: 116.116
• InChiKey: UWIVVFQECQYHOB-UHFFFAOYSA-M

物化性质

• 熔点：
  292°C
• 密度：
  1.372

计算性质

• 辛醇/水分配系数(LogP)：
  -3.11
• 重原子数：
  6
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  59.3
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2930909090
• WGK Germany：
  3
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储条件：2～8℃，干燥处，密封保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Sodium ethanesulfinate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Sodium ethanesulfinate
CAS number: 20035-08-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C2H5O2S.Na
Molecular weight: 116.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  乙烷亚磺酸钠 在 碘 作用下， 以 乙醇 、 水 为溶剂， 生成 ethanesulfonyl iodide
  参考文献：
  名称：

  铜催化的具有磺酰碘的丙二烯双官能化导致（E）-α-碘甲基乙烯基砜

  摘要：

  已经开发了在CuI和1,10-菲咯啉存在下，丙二烯的高度区域选择性的碘磺酰化，用于以中等至优异的产率合成各种有用的（E）-α-碘甲基乙烯基砜。该实际反应快速，操作简单，并且特别是在非常温和的条件下进行，以提供具有高区域选择性和立体选择性的目标产物。通过概念性DFT分析说明了选择性。

  DOI：

  10.1021/acs.orglett.8b01765
• 作为产物：
  描述：

  乙基磺酰氯 在 sodium sulfide 、 碳酸氢钠 作用下， 以 水 为溶剂， 反应 2.0h， 以96%的产率得到乙烷亚磺酸钠
  参考文献：
  名称：

  One-pot synthesis of symmetric 1,7-dicarbonyl compounds via a tandem radical addition–elimination–addition reaction

  摘要：

  一种新方法已经被开发，通过S-羰基甲基黄嘌呤与环基甲基亚砜及其类似物的串联自由基加成–消除–加成反应合成对称的1,7-二羰基化合物。自由基是通过向S-羰基甲基黄嘌呤中添加二月桂油过氧化物生成的，并与环基甲基亚砜或其类似物反应生成末端烯烃作为中间体。过量的自由基立即与中间烯烃反应，形成对称的1,7-二羰基化合物的加合物。这是一种在温和条件下合成1,7-二羰基化合物的高效方法。

  DOI：

  10.1039/c3ra42932f
• 作为试剂：
  描述：

  1-methyl-2(1H)-quinoxalinone 、 iodobenzene dipropionate 在 乙烷亚磺酸钠 作用下， 以82%的产率得到3-ethyl-1-methylquinoxalin-2(1H)-one
  参考文献：
  名称：

  无催化剂的Minisci型反应：喹喔啉酮与烷基亚磺酸钠和苯基碘（III）二羧酸的CH烷基化

  摘要：

  在无催化剂的条件下，已开发了在烷基的C-3位置与烷基亚磺酸钠和苯基碘（III）二羧酸直接对喹喔啉酮进行CH烷基化反应。在该方案中，以中等到极好的产率提供了一系列3-烷基喹喔啉酮，这为生物学上令人感兴趣的3-烷基喹喔啉-2（1 H）-one衍生物提供了实用而有效的途径。

  DOI：

  10.1002/ejoc.201901266

文献信息

• Rethinking Cysteine Protective Groups:<i>S</i>-Alkylsulfonyl-<scp>l</scp>-Cysteines for Chemoselective Disulfide Formation
  作者：Olga Schäfer、David Huesmann、Christian Muhl、Matthias Barz

  DOI：10.1002/chem.201604391

  日期：2016.12.12

  The ability to reversibly cross‐link proteins and peptides grants the amino acid cysteine its unique role in nature as well as in peptide chemistry. We report a novel class of S‐alkylsulfonyl‐l‐cysteines and N‐carboxy anhydrides (NCA) thereof for peptide synthesis. The S‐alkylsulfonyl group is stable against amines and thus enables its use under Fmoc chemistry conditions and the controlled polymerization

  可逆性交联蛋白质和多肽的能力使氨基酸半胱氨酸在自然界以及多肽化学中具有独特的作用。我们报告了一类新型的S-烷基磺酰基-L-半胱氨酸和N-羧基酐（NCA）用于肽合成。该小号烷基磺酰基是针对胺稳定的，因此使它的Fmoc化学条件和相应的种NCA屈服良好定义的均聚物以及嵌段共聚物的受控聚合下使用。然而，硫醇会立即与S反应-烷基磺酰基形成不对称的二硫化物。因此，我们引入了第一个反应性半胱氨酸衍生物，以在合成多肽中有效和化学选择性地形成二硫化物，从而绕开了其他保护基团的裂解步骤。
• [EN] KCNT1 INHIBITORS AND METHODS OF USE<br/>[FR] INHIBITEURS DE KCNT1 ET PROCÉDÉS D'UTILISATION
  申请人：PRAXIS PREC MEDICINES INC

  公开号：WO2020227097A1

  公开（公告）日：2020-11-12

  The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.

  本发明部分涉及用于预防和/或治疗神经系统疾病或紊乱、与过度神经元兴奋性有关的疾病或症状，以及基因中的功能增强突变（例如，KCNT1）的化合物和组合物。本文还提供了治疗神经系统疾病或紊乱、与过度神经元兴奋性有关的疾病或症状，以及基因中的功能增强突变（如KCNT1）的方法。
• [EN] TRPV4 ANTAGONISTS<br/>[FR] ANTAGONISTES DE TRPV4
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2011119701A1

  公开（公告）日：2011-09-29

  The present invention relates to quinoline analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.

  本发明涉及喹啉类似物、含有它们的药物组合物以及它们作为TRPV4拮抗剂的用途。
• [EN] CYP11A1 INHIBITORS<br/>[FR] INHIBITEURS DE CYP11A1
  申请人：ORION CORP

  公开号：WO2021229152A1

  公开（公告）日：2021-11-18

  The present invention relates to a compound of formula (I) or (II) wherein R1, R2, R3, R4, R5, R23, R24, R25, R26, R27, L, A and B are as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) or (II) possess utility as cytochrome P450 monooxygenase 11A1 (CYP11A1) inhibitors. The compounds are useful as medicaments in the treatment of steroid receptor, particularly androgen receptor, dependent diseases and conditions, such as prostate cancer.

  本发明涉及一种具有式（I）或（II）的化合物，其中R1、R2、R3、R4、R5、R23、R24、R25、R26、R27、L、A和B如权利要求书中所定义，或其药学上可接受的盐。式（I）或（II）的化合物具有作为细胞色素P450单加氧酶11A1（CYP11A1）抑制剂的效用。这些化合物在治疗类固醇受体，特别是雄激素受体依赖性疾病和症状，如前列腺癌中作为药物是有用的。
• [EN] PYRIDYL OR PYRIMIDYL MTOR KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE MTOR DE PYRIDYLE OU DE PYRIMIDYLE
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2020249652A1

  公开（公告）日：2020-12-17

  The invention relates to compounds or pharmaceutically acceptable salts thereof of formula (I): (I) wherein R1, R2, R3, R4, R4' and R5 are as defined in the description and claims; and compounds or pharmaceutically acceptable salts thereof of formulas (II), (IIa), (IIb), (IIc), and (III) having mTOR kinase inhibitor activity. The invention also relates to pharmaceutical compositions which include a compound of formula (I), (II), (IIa), (IIb), (IIc), or (III) or a pharmaceutically acceptable salt thereof, and to the use of a compound of formula (I), (II), (IIa), (IIb), (IIc), or (III), or a pharmaceutically acceptable salt thereof in therapy, including in the treatment of a disease or condition for which an mTOR kinase inhibitor activity is indicated, and in particular the treatment of idiopathic pulmonary fibrosis.

  该发明涉及化合物或其药用可接受盐的公式(I)：（I）其中R1、R2、R3、R4、R4'和R5如描述和索赔中定义；以及具有mTOR激酶抑制剂活性的公式(II)、(IIa)、(IIb)、(IIc)和(III)的化合物或其药用可接受盐。该发明还涉及包括公式(I)、(II)、(IIa)、(IIb)、(IIc)或(III)的化合物或其药用可接受盐的药物组合物，以及在治疗中使用公式(I)、(II)、(IIa)、(IIb)、(IIc)或(III)的化合物或其药用可接受盐，包括治疗需要mTOR激酶抑制剂活性的疾病或症状，特别是治疗特发性肺纤维化。